Aker BioMarine - Public Comps and Valuation Multiples

Aker BioMarine Overview

About Aker BioMarine

Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Ingredients, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.

Founded

2006

HQ

Employees

255

Website

akerbiomarine.com

Sectors

Food & Beverages

Financials

LTM Revenue $2.6B

LTM EBITDA $401M

EV

$643M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Aker BioMarine Financials

Aker BioMarine has a last 12-month revenue (LTM) of $2.6B and a last 12-month EBITDA of $401M.

In the most recent fiscal year, Aker BioMarine achieved revenue of $19.5M and an EBITDA of $3.5M.

Aker BioMarine expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Aker BioMarine valuation multiples based on analyst estimates

Aker BioMarine P&L

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.6B	XXX	$19.5M	XXX	XXX	XXX
Gross Profit	$885M	XXX	$6.8M	XXX	XXX	XXX
Gross Margin	35%	XXX	35%	XXX	XXX	XXX
EBITDA	$401M	XXX	$3.5M	XXX	XXX	XXX
EBITDA Margin	16%	XXX	18%	XXX	XXX	XXX
EBIT	$94.2M	XXX	-$0.7M	XXX	XXX	XXX
EBIT Margin	4%	XXX	-4%	XXX	XXX	XXX
Net Profit	-$64.7M	XXX	$17.6M	XXX	XXX	XXX
Net Margin	-3%	XXX	91%	XXX	XXX	XXX
Net Debt	XXX	XXX	$12.7M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Aker BioMarine Stock Performance

As of May 30, 2025, Aker BioMarine's stock price is NOK 59 (or $6).

Aker BioMarine has current market cap of NOK 5.2B (or $510M), and EV of NOK 6.6B (or $643M).

See Aker BioMarine trading valuation data

Aker BioMarine Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$643M	$510M	XXX	XXX	XXX	XXX	$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Aker BioMarine Valuation Multiples

As of May 30, 2025, Aker BioMarine has market cap of $510M and EV of $643M.

Aker BioMarine's trades at 33.1x EV/Revenue multiple, and 183.8x EV/EBITDA.

Equity research analysts estimate Aker BioMarine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Aker BioMarine has a P/E ratio of -80.6x.

See valuation multiples for Aker BioMarine and 12K+ public comps

Aker BioMarine Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$510M	XXX	$510M	XXX	XXX	XXX
EV (current)	$643M	XXX	$643M	XXX	XXX	XXX
EV/Revenue	2.6x	XXX	33.1x	XXX	XXX	XXX
EV/EBITDA	16.4x	XXX	183.8x	XXX	XXX	XXX
EV/EBIT	69.8x	XXX	-865.6x	XXX	XXX	XXX
EV/Gross Profit	7.4x	XXX	n/a	XXX	XXX	XXX
P/E	-80.6x	XXX	28.9x	XXX	XXX	XXX
EV/FCF	3.1x	XXX	-603.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Aker BioMarine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Aker BioMarine Margins & Growth Rates

Aker BioMarine's last 12 month revenue growth is -6%

Aker BioMarine's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $29K for the same period.

Aker BioMarine's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aker BioMarine's rule of X is 1% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Aker BioMarine and other 12K+ public comps

Aker BioMarine Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-6%	XXX	259%	XXX	XXX	XXX
EBITDA Margin	16%	XXX	18%	XXX	XXX	XXX
EBITDA Growth	18%	XXX	184%	XXX	XXX	XXX
Rule of 40	9%	XXX	12%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	1%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$29K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	16%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	39%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial